Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bortezomib
  • Multiple Myeloma

abstract

  • Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.

publication date

  • November 20, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.58.7618

PubMed ID

  • 26056177

Additional Document Info

start page

  • 3921

end page

  • 9

volume

  • 33

number

  • 33